219 related articles for article (PubMed ID: 34115754)
1. Feasibility of a dried blood spot strategy for serological screening and surveillance to monitor elimination of Human African Trypanosomiasis in the Democratic Republic of the Congo.
Inocencio da Luz R; Phanzu DM; Kiabanzawoko ON; Miaka E; Verlé P; De Weggheleire A; Büscher P; Hasker E; Boelaert M
PLoS Negl Trop Dis; 2021 Jun; 15(6):e0009407. PubMed ID: 34115754
[TBL] [Abstract][Full Text] [Related]
2. Development and implementation of a strategy for intensified screening for gambiense human African trypanosomiasis in Kongo Central province, DRC.
Lumbala C; Kayembe S; Makabuza J; Lutumba P; Van Geertruyden JP; Bessell PR; Ndung'u JM
PLoS Negl Trop Dis; 2020 Oct; 14(10):e0008779. PubMed ID: 33057341
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of human African trypanosomiasis in the Democratic Republic of the Congo.
Mumba D; Bohorquez E; Messina J; Kande V; Taylor SM; Tshefu AK; Muwonga J; Kashamuka MM; Emch M; Tidwell R; Büscher P; Meshnick SR
PLoS Negl Trop Dis; 2011 Aug; 5(8):e1246. PubMed ID: 21829736
[TBL] [Abstract][Full Text] [Related]
4. Monitoring the elimination of gambiense human African trypanosomiasis in the historical focus of Batié, South-West Burkina Faso.
Compaoré CFA; Kaboré J; Ilboudo H; Thomas LF; Falzon LC; Bamba M; Sakande H; Koné M; Kaba D; Bougouma C; Adama I; Amathe O; Belem AMG; Fèvre EM; Büscher P; Lejon V; Jamonneau V
Parasite; 2022; 29():25. PubMed ID: 35543528
[TBL] [Abstract][Full Text] [Related]
5. Human African trypanosomiasis in the Democratic Republic of the Congo: disease distribution and risk.
Lumbala C; Simarro PP; Cecchi G; Paone M; Franco JR; Kande Betu Ku Mesu V; Makabuza J; Diarra A; Chansy S; Priotto G; Mattioli RC; Jannin JG
Int J Health Geogr; 2015 Jun; 14():20. PubMed ID: 26047813
[TBL] [Abstract][Full Text] [Related]
6. Trypanosomiasis control, Democratic Republic of Congo, 1993-2003.
Lutumba P; Robays J; Miaka mia Bilenge C; Mesu VK; Molisho D; Declercq J; Van der Veken W; Meheus F; Jannin J; Boelaert M
Emerg Infect Dis; 2005 Sep; 11(9):1382-8. PubMed ID: 16229766
[TBL] [Abstract][Full Text] [Related]
7. Health care-seeking behaviour and diagnostic delays for Human African Trypanosomiasis in the Democratic Republic of the Congo.
Hasker E; Lumbala C; Mbo F; Mpanya A; Kande V; Lutumba P; Boelaert M
Trop Med Int Health; 2011 Jul; 16(7):869-74. PubMed ID: 21447063
[TBL] [Abstract][Full Text] [Related]
8. Performance of clinical signs and symptoms, rapid and reference laboratory diagnostic tests for diagnosis of human African trypanosomiasis by passive screening in Guinea: a prospective diagnostic accuracy study.
Camara O; Camara M; Falzon LC; Ilboudo H; Kaboré J; Compaoré CFA; Fèvre EM; Büscher P; Bucheton B; Lejon V
Infect Dis Poverty; 2023 Mar; 12(1):22. PubMed ID: 36941656
[TBL] [Abstract][Full Text] [Related]
9. Data-driven models to predict the elimination of sleeping sickness in former Equateur province of DRC.
Rock KS; Pandey A; Ndeffo-Mbah ML; Atkins KE; Lumbala C; Galvani A; Keeling MJ
Epidemics; 2017 Mar; 18():101-112. PubMed ID: 28279451
[TBL] [Abstract][Full Text] [Related]
10. [Epidemiological, clinical and sociodemographic characteristics of human African trypanosomiasis (HAT) in and around Kinshasa, Democratic Republic of Congo].
Tshimungu K; Okenge LN; Mukeba JN; Kande VB; De Mol P
Sante; 2009; 19(2):73-80. PubMed ID: 20031514
[TBL] [Abstract][Full Text] [Related]
11. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial.
Priotto G; Kasparian S; Mutombo W; Ngouama D; Ghorashian S; Arnold U; Ghabri S; Baudin E; Buard V; Kazadi-Kyanza S; Ilunga M; Mutangala W; Pohlig G; Schmid C; Karunakara U; Torreele E; Kande V
Lancet; 2009 Jul; 374(9683):56-64. PubMed ID: 19559476
[TBL] [Abstract][Full Text] [Related]
12. Predicting the impact of COVID-19 interruptions on transmission of gambiense human African trypanosomiasis in two health zones of the Democratic Republic of Congo.
Aliee M; Castaño S; Davis CN; Patel S; Miaka EM; Spencer SEF; Keeling MJ; Chitnis N; Rock KS
Trans R Soc Trop Med Hyg; 2021 Mar; 115(3):245-252. PubMed ID: 33611586
[TBL] [Abstract][Full Text] [Related]
13. The elimination of human African trypanosomiasis: Monitoring progress towards the 2021-2030 WHO road map targets.
Franco JR; Priotto G; Paone M; Cecchi G; Ebeja AK; Simarro PP; Sankara D; Metwally SBA; Argaw DD
PLoS Negl Trop Dis; 2024 Apr; 18(4):e0012111. PubMed ID: 38626188
[TBL] [Abstract][Full Text] [Related]
14. Performance of parasitological and molecular techniques for the diagnosis and surveillance of gambiense sleeping sickness.
Mumba Ngoyi D; Ali Ekangu R; Mumvemba Kodi MF; Pyana PP; Balharbi F; Decq M; Kande Betu V; Van der Veken W; Sese C; Menten J; Büscher P; Lejon V
PLoS Negl Trop Dis; 2014 Jun; 8(6):e2954. PubMed ID: 24921941
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic accuracy and feasibility of serological tests on filter paper samples for outbreak detection of T.b. gambiense human African trypanosomiasis.
Hasker E; Lutumba P; Mumba D; Lejon V; Büscher P; Kande V; Muyembe JJ; Menten J; Robays J; Boelaert M
Am J Trop Med Hyg; 2010 Aug; 83(2):374-9. PubMed ID: 20682885
[TBL] [Abstract][Full Text] [Related]
16. Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study.
Kande Betu Ku Mesu V; Mutombo Kalonji W; Bardonneau C; Valverde Mordt O; Ngolo Tete D; Blesson S; Simon F; Delhomme S; Bernhard S; Mahenzi Mbembo H; Mpia Moke C; Lumeya Vuvu S; Mudji E'kitiak J; Akwaso Masa F; Mukendi Ilunga M; Mpoyi Muamba Nzambi D; Mayala Malu T; Kapongo Tshilumbwa S; Botalema Bolengi F; Nkieri Matsho M; Lumbala C; Scherrer B; Strub-Wourgaft N; Tarral A
Lancet Glob Health; 2021 Jul; 9(7):e999-e1008. PubMed ID: 34143998
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of Nifurtimox Eflornithine Combination Therapy (NECT) in T. b. gambiense second stage sleeping sickness patients in the Democratic Republic of Congo: Report from a field study.
Kuemmerle A; Schmid C; Bernhard S; Kande V; Mutombo W; Ilunga M; Lumpungu I; Mutanda S; Nganzobo P; Tete DN; Kisala M; Burri C; Blesson S; Valverde Mordt O
PLoS Negl Trop Dis; 2021 Nov; 15(11):e0009903. PubMed ID: 34748572
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity and specificity of HAT Sero-K-SeT, a rapid diagnostic test for serodiagnosis of sleeping sickness caused by Trypanosoma brucei gambiense: a case-control study.
Büscher P; Mertens P; Leclipteux T; Gilleman Q; Jacquet D; Mumba-Ngoyi D; Pyana PP; Boelaert M; Lejon V
Lancet Glob Health; 2014 Jun; 2(6):e359-63. PubMed ID: 25103304
[TBL] [Abstract][Full Text] [Related]
19. Treatment outcomes and risk factors for relapse in patients with early-stage human African trypanosomiasis (HAT) in the Republic of the Congo.
Balasegaram M; Harris S; Checchi F; Hamel C; Karunakara U
Bull World Health Organ; 2006 Oct; 84(10):777-82. PubMed ID: 17128357
[TBL] [Abstract][Full Text] [Related]
20. Assessing the impact of aggregating disease stage data in model predictions of human African trypanosomiasis transmission and control activities in Bandundu province (DRC).
Castaño MS; Ndeffo-Mbah ML; Rock KS; Palmer C; Knock E; Mwamba Miaka E; Ndung'u JM; Torr S; Verlé P; Spencer SEF; Galvani A; Bever C; Keeling MJ; Chitnis N
PLoS Negl Trop Dis; 2020 Jan; 14(1):e0007976. PubMed ID: 31961872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
